Skip to main content
OpenTrials
Completed

NCT Number: NCT02522546

A Study to Assess the Carriage of Pneumococci in Children Aged 1-5 Years, and Their Household Contacts

Pneumococci are bacteria which can cause serious and potentially life threatening illnesses like meningitis and blood poisoning.

Pneumococcal vaccines (PCV) have been given in the national immunisation schedule since 2006.Carriage studies allow assessment of how the strains in the nose change over time, in that by clearing some strains away which other strains take up those niches in their place both in children and in their close/household contacts. This helps to inform the best use of the vaccines available and for future vaccine development and which strains would be useful to include.

Completed

Looking for future studies?

Notify Me

Key information

Age range

1 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Gloucestershire primary care, Gloucestershire, United Kingdom

Loading trial locations.

About this study

Pneumococci are bacteria which can cause serious and potentially life threatening illnesses like meningitis and blood poisoning. There are ~90 strains, some are more dangerous than others in the severity of the disease they cause. Around half of all children carry pneumococci at the back of their nose without any ill effect. Pneumococcal vaccines (PCV) have been given in the national immunisation schedule since 2006. Vaccines protect individuals by making antibodies to be made in the blood and these vaccines help to clear the pneumococci from the nose, which helps control disease in the population by stopping their onward transmission when children cough and sneeze. This clearing effect is specific to the strains that are included in the vaccine. The first vaccines used included seven (PCV7) strains and the one used currently includes 13 (PCV13).

This group has conducted three previous carriage studies, and this will be the fourth. The first was before any vaccine was used, the second just after PCV7 was introduced and the third after the UK moved to using PCV13. These carriage studies allow assessment of how the strains in the nose change over time, in that by clearing some strains away which other strains take up those niches in their place both in children and in their close/household contacts. This helps to inform the best use of the vaccines available and for future vaccine development and which strains would be useful to include.

All families registered at participating surgeries, with a child aged 1-5 years, will be invited to take part. The study involves a single nasopharyngeal swab and a saliva swab from the child and as many other household members as are happy to participate. Participants may be seen at their GP surgery or in the home if more mutually convenient

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least one child aged 1 to 5 years in the household
  • Written informed consent obtained from the child's parent / legal guardian for their participation, and for any participating household contacts

Exclusion criteria

  • Moderate to severe cerebral palsy or other debilitating condition
  • Syndromes and neurological disorders affecting swallowing.
  • Ear, nose & throat disorders affecting local anatomy for swabbing (e.g. malformed ears)
  • Confirmed or suspected immunodeficiency (congenital or acquired) or receiving immunosuppressive therapy.

Treatment and study plan

Nasopharyngeal Swab

Other

nasopharyngeal swab

Other names: nose swab

Primary outcomes

  1. pneumococcal carriage rate in children aged 1-5 years, older children and adolescents (aged 5-20 years) and adults (aged >20 years), five years after the introduction of PCV13

    Time frame: baseline

    pneumococcal carriage rates for PCV13 and non-PCV13 serotypes in children aged 1-5 years, older children and adolescents (aged 5-20 years) and adults (aged >20 years), five years after the introduction of PCV13.

  2. invasiveness of any emerging replacement carriage serotype

    Time frame: baseline

    invasiveness of any emerging replacement carriage serotypes by estimating case: carrier ratio (CCR) using national surveillance data for invasive pneumococcal disease

Secondary outcomes

  1. carriage rates of individual serotype

    Time frame: baseline

  2. changes in carriage serotype

    Time frame: baseline

    changes in carriage serotype, by age, vs previous carriage studies performed by the Health Protection Agency in 2001/02, 2008/09 and 2012 in children and adults. This includes changes in the prevalence of proportion and changes in the proportion of carriage strains that are vaccine and non-vaccine types

Sponsors and collaborators

Lead sponsor

Public Health England

Other Gov

Registry information

Acronym: PIN

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Aug 13, 2015
Registry last updated
Mar 22, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.